Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on MedinCell SA, with a price target of €32.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ram Selvaraju has given his Buy rating due to a combination of factors related to MedinCell SA’s promising long-acting injectable (LAI) portfolio. The company’s collaboration with Teva Pharmaceutical Industries has shown significant market potential, particularly with the UZEDY product, which has seen increased sales forecasts. Selvaraju anticipates that UZEDY could achieve over $300 million in U.S. sales by 2025, with further growth expected in 2026. Additionally, the potential FDA approval for UZEDY’s use in treating bipolar disorder I could expand its market reach, enhancing MedinCell’s revenue prospects.
Moreover, the upcoming launch of Teva’s olanzapine LAI, which has demonstrated favorable safety results, is expected to further boost MedinCell’s top-line revenue. Selvaraju views the atypical antipsychotic LAI market as a rapidly growing segment, driven by the preference for LAI drugs among prescribers and patients. With Teva’s strategic positioning and the absence of direct competitors for its olanzapine LAI, Selvaraju believes MedinCell is well-positioned for long-term success, leading to an increased price target of €32.
In another report released on September 23, Kepler Capital also maintained a Buy rating on the stock with a €25.60 price target.